Engineered immune cells take on lupus in early trial
NCT ID NCT06946485
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This early-phase study tests a new treatment called CHT101, which uses specially engineered immune cells (CAR-T cells) to target and attack faulty cells in people with severe lupus that hasn't improved with standard treatments. The trial will enroll 15 participants to check if the therapy is safe and whether it can reduce lupus disease activity. It is a first step, so the main goals are safety and seeing any signs of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
RECRUITINGNanjing, Jiangsu, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
universal anti-CD70 CAR-T cells (CHT101)
What this could lead to
If successful, this could offer a new treatment option for people with severe lupus that hasn't responded to standard therapies.
What could go wrong
This is a very early, small study (15 people) focused on safety. CAR-T therapy carries risks like severe immune reactions, and it's unknown if it will work for lupus long-term.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.